Introdução: A alergia a veneno de himenópteros está associada a uma significativa morbilidade e diminuição da qualidade de vida, bem como a risco de reações alérgicas fatais. Apesar da imunoterapia com veneno de himenópteros ser um tratamento seguro e o único eficaz nesta patologia, alguns doentes decidem não o realizar. 
INTRODUCTION
Hymenoptera venom allergy (HVA) is generally a serious life-threatening condition and it is responsible for more than 10% of all cases of anaphylaxis attending emergency departments. 1 It affects up to 5% of the general population 2 and up to 32% of beekeepers. 3 Epidemiological studies suggest a prevalence of self-reported anaphylactic sting reactions between 0.3% and 7.5%. 4 Hymenoptera reactions are responsible for about a quarter of fatalities due to anaphylaxis. 5 Moreover, due to the fear of future reactions, HVA imposes a significant impact in health-related quality of life (QoL) 6 and causes work disability. 7 Numerous insects can induce allergic reactions. However only the insect stings of the order Hymenoptera can cause fatal reactions. From a medical perspective, the more relevant ones belong to the families vespidae, apidae and fomicidae; in Europe only Apidae (apis mellifera and bombus terrestris) and Vespidae (vespula, vespa, polistes) are pertinent. 8 Every patient reporting a systemic allergic reaction after a sting should undergo a complete allergy work-up, which should include a detailed history, specific IgE to suspected hymenoptera venom and basal serum tryptase measurements, prick and intradermal skin tests to the suspected insect venom. 9, 10 Management of HVA is based on avoidance measures, availability of emergency treatment and venom immunotherapy (VIT). 6, 9, 10 VIT is the only treatment option with an immunomodulatory effect that results in a decreased risk Carneiro-Leão L, et al. Reasons for declining venom immunotherapy, Acta Med Port 2018 Nov;31 (11):618-623 and severity of future sting induced systemic reactions. 6, 9, 10 VIT is safe and induces tolerance to hymenoptera venom, providing long-term protection from further systemic reactions in 95% of patients allergic to wasp venom, and approximately 80% of those allergic to bee venom. 11 However, the mechanism behind this tolerance induction is not fully understood. It also improves health related QoL. 12, 13 VIT should be offered to children and adults with a history of severe systemic reaction and documented sensitization to the respective insect with either positive skin tests and/ or elevated specific IgE. 6, 9, 10, 14 Unless additional risk factors are present (raised baseline tryptase, a high likelihood of future sting or impact on QoL), VIT is usually not indicated for less severe sting induced reactions. 6, [9] [10] [11] Essentially, VIT consists in the subcutaneous administration of the selected venom extract, with an initial induction phase, followed by a maintenance phase. In the induction phase serial doses of venom extract are administered, building-up until a protective dose of 100 µg of venom extract is reached. Induction protocols are varied, lasting from 2 to 6 weeks. Maintenance phase consists in the administration of 100 µg of venom extract at scheduled intervals. There is a generalized consensus that intervals should be of 4 weeks for the first year and may then be extended to 6 weeks The overall duration of VIT is 3 to 5 years but can be longer in selected patients.
6,9,10 VIT administration carries a small but serious risk of anaphylaxis and, for that reason, it should be managed by an experienced allergist, in a hospital setting. 6, 9, 10 In addition to being time consuming, VIT is also costly. Venom extracts are commercially available for honeybee, wasp and paper wasp. In 2012, National Institute for Health and Care Excellence (NICE) estimated a cost per injection of £54.81 for bee venom, and of £67.20 for wasp venom extract during the induction phase; for maintenance, the price per injection varied from £15.94 for bee venom, to £20.51 to wasp venom extract. 15 In Portugal, prices per injection vary from €37.6 to €124.20 during induction and from €36.04 to €47.85 during the maintenance phase. A small Portuguese study concluded that the median yearly cost of VIT was €1549, including €438 for VIT extract purchase, €218 for hospital visits, and €787 for work hours loss. 16 Allergen immunotherapy had a 50% reimbursement by the National Health Service in Portugal until it was stopped in 2011, a period of economic and financial crisis. This decision was contested by physicians, patients, the national allergy and clinical immunology scientific society and the Portuguese Medical Association. Nonetheless, reimbursement was stopped and so the burden of VIT became entirely supported by the patients.
The purpose of this study was to examine the reasons why patients declined VIT, as well as to assess the impact of VIT price and reimbursement withdrawal on their decision.
MATERIAL AND METHODS
Medical records of all patients with clinical indication for 17 suspected hymenoptera involved, specific IgE, venom skin tests, type of VIT proposed, dates of proposal, first and last administration and treatment completion was collected. Premature interruption was defined when the patient stopped VIT before the scheduled date. The term price refers to the amount spent by patients for purchasing the relevant hymenoptera venom extract (commonly known as 'allergen vaccine'); cost refers to the total amount of money spent during treatment, including hospital visits, work hours lost, etc.
A structured questionnaire was applied by phone to patients who had declined VIT (Fig. 1) . Information was gathered on the reasons why patients decided against VIT, new field stings (accidental hymenoptera stings), severity of subsequent reactions and use of adrenaline auto-injectors (AAI).
Statistical analysis was performed using IBM SPSS Statistics ® , version 20.0. Continuous variables are expressed as means and standard deviations; categorical variables were expressed as frequencies and percentages. Independent t-test was used to compare mean age between groups. Chi-squared test, which tests whether two categorical variables are independent or not, was used to identify differences among groups. Risk factors for VIT refusal were assessed using univariate binary logistic regression analysis, using age, sex, comorbid allergic diseases, type of profession (primary, secondary or tertiary sectors), type of VIT proposed, severity of previous reactions, feeling of impending doom during the reactions and VIT being proposed after 2011 as independent variables. Assessment of the discriminatory performance of the model was conducted using Nagelkerke R² and area under the receiver-operating curve (AUC). The results are expressed as odds ratios (ORs) and 95% confidence intervals (CIs); p < 0.05 was considered statistically significant.
RESULTS
A total of 83 patients had indication for VIT, 44 (53%) between 2006 and 2010 and 39 (47%) between 2011 and 2015. No significant differences were detected between the two groups besides the number of patients refusing VIT: 27 refused treatment, 9 (21%) of them in 2006 -2010 period and 18 (46%) in the 2011 -2015 period (χ2 (1) = 6.221; p = 0.013). The patient flow chart is illustrated in Fig. 2 . Table 1 presents the clinical characteristics of patients refusing and undergoing VIT. Also, nine patients decided to stop VIT prematurely, eight of them after 2011. Univariate logistic regression identified being proposed after 2011 as the only variable contributing to VIT refusal and it was strongly associated to a higher risk of refusal (OR: 3.29; 95% CI: 1.12 -9.68; p = 0.03) (results shown in Table 2 ). Assessment of the discriminatory performance of the model revealed Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com a poor predictive capacity: low Nagelkerke R² (0.101) and AUC (0.646).
Phone interviews
Nineteen of the 27 patients declining VIT agreed to be interviewed by phone. Of these, 17 (89%) stated that price influenced their decision not to undergo VIT; 14 (73.7%) identified it as the major reason for declining treatment and 4 (21.1%) indicated difficulties in obtaining time off work once a month for hospital visits. Seventeen (89.5%) and 10 (52.6%) would have accepted VIT if it was fully or partially reimbursed (50%), respectively. Since refusing VIT, 11 (57.9%) were re-stung and 9 of them had another anaphylactic episode with 7 attending an emergency department. No fatalities or hospitalizations were reported. One patient changed profession, 5 changed hobbies and another 5 avoided outdoor activities because of this allergy. Seven admitted not purchasing nor carrying their prescribed AAI. Six of these stated they would have redeemed their prescription if it was 50% cheaper.
DISCUSSION
VIT is the first line of treatment in hymenoptera venom allergic patients suffering severe systemic reactions with documented sensitization to the suspected insect. However, this treatment is expensive and, in Portugal, the onus is entirely supported by patients since 2011. In this series, a significant increase in the number of patients refusing treatment was observed since the reimbursement was withdrawn. A greater than two-fold increase was found when comparing the 5-year periods before and after the changes in reimbursement policy. Furthermore, VIT being proposed after 2011 was the only identified risk-factor for not undergoing this treatment, with a greater than threefold increase in this risk. However, this last result should be interpreted carefully, as the model on which it was based showed a poor performance on discriminatory assessment measures -although these results were to be expected, given the small sample size and the characteristics of the variables included in the model. Phone interviews with the patients refusing VIT further confirmed the impact of price in treatment adherence, as the vast majority identified this as the major reason to decline treatment. VIT is an expensive treatment, especially if all associated costs are considered, including not only its price, but also work hours lost and the cost of hospital visits. In 2016, the average wage in Portugal was €924, 18 remaining below the European average; in 2016, 23.3% of workers earned the minimum wage of €557. 19, 20 In this setting, it seems reasonable to expect that the average Portuguese individual will struggle to support all treatment expenses.
Price was again reported as an obstacle for carrying an AAI. Patient safety was indeed impaired since a significant percentage suffered new field stings and subsequent anaphylaxis.
VIT safety and clinical efficacy are well established. Although its cost-effectiveness has been a matter of debate, a NICE health technology assessment showed that when patients at a high risk of stings or when a small increase in QoL are considered, VIT is a cost-effective treatment. 15 Taking these characteristics into consideration, the 2011 decision to stop reimbursement is debatable from a clinical and health economics standpoint.
This study was limited by its retrospective design, the For years Portuguese allergists have sensed that patients were refusing VIT for economic reasons. Our study is the first confirming this perception and providing evidence of the negative impact of the decision to stop VIT reimbursement.
CONCLUSION
These results illustrate how economic decisions may have a negative impact on patient adherence to treatment, safety and wellbeing. In this particular case, a detrimental effect on patient care was observed since VIT refusal exposed them to an avoidable life-threatening risk. As the ultimate patient advocates, doctors must be aware of these consequences and defend patients. 
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